Seelos Therapeutics, Inc. SEEL
Nov 18, 2024, 3:58 PM EST
52-week range unavailable
- YTD
- -71.09%
- 1 year
- -71.09%
- Market cap
- 214.97K
- Revenue (ttm)
- 2.01M
- Profit margin
- 203.13%
- Shares out
- 581.00K
- Forward P/E
- -0.28
- YTD return
- -71.09%
- 1-year return
- -71.09%
- Previous close
- 0.37
- Day's range
- 0.37 – 0.37
- Beta
- 1.94
- Earnings date
- Nov 19, 2024
2Y -2,775.3000 (-99.99%)
Key statistics
- Enterprise value
- 9.99M
- PEG ratio
- 0.00
- Price / sales
- 0.11
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 11.90%
- Free cash flow
- -34.28M
- Total cash
- 294.00K
- Total debt
- 10.16M
- Return on equity
- 0.00%
- Short % of float
- 29.52%
- 50-day average
- 1.87
- 200-day average
- 29.73
Next earnings
Nov 19, 2024
Expected Nov 19, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 19, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 12, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Oct 6, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- seelostherapeutics.com
News
"RFK Says Trump Administration Could Provide Psychedelic Therapy To Military Veterans 'Within 12 Months'" - Marijuana Moment 
'Psychedelics Proponents Hope Trump Administration Will Foster A New Era' - STAT News 
Seelos Announces Second Postponement of its Annual Meeting of Stockholders 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market 
Seelos Announces Postponement of its Annual Meeting of Stockholders 
Seelos Therapeutics Announces 1-for-16 Reverse Stock Split 
Crude Oil Gains Over 1%; BioVie Shares Plunge 
Nasdaq Surges 100 Points; Thor Industries Earnings Top Views - Dow Rises Over 50 Points; AutoZone Posts Downbeat Earnings
Your note
Sign in to keep a note on SEEL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOLEMBIEWSKI MICHAEL JOSEPH | Chief Financial Officer | Stock Award(Grant) | Feb 28, 2024 | 86,869 |
| MEHRA RAJ | Chief Executive Officer | Purchase | Nov 30, 2023 | 185,142 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Investments, LLC | 1.61% | 18,113 | 6.70K | Sep 29, 2024 |
| Modera Wealth Management, LLC | 0.96% | 10,805 | 4.00K | Sep 29, 2024 |
| UBS Group AG | 0.75% | 8,477 | 3.14K | Sep 29, 2024 |
| Morgan Stanley | 0.06% | 675 | 249 | Sep 29, 2024 |
| Blackrock Inc. | 0.03% | 354 | 130 | Sep 29, 2024 |
| Carmichael Hill & Associates, Inc. | 0.01% | 62 | 22 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 1.61% | 18,113 | 6.70K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.18% | 2,054 | 759 | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.04% | 437 | 161 | Jun 29, 2024 |
| Fidelity Total Market Index Fund | 0.00% | 51 | 18 | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.00% | 41 | 15 | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.00% | 22 | 8 | Sep 29, 2024 |